Categories
Archives
Receive Email Updates
-
-
Certified Licensing Professionals, Inc., 2021 Disclaimer
This blog, Patents4Life, does not contain legal advice and is for informational purposes only. Its publication does not create an attorney-client relationship nor is it a solicitation for business. This is the personal blog of Warren Woessner and does not reflect the views of Schwegman Lundberg & Woessner, or any of its attorneys or staff. To the best of his ability, the Author provides current and accurate information at the time of each post, however, readers should check for current information and accuracy.
- About Me
Warren D. Woessner Pages
Archives
Tag Archives: Chakrabarty
Chromadex v. Elysium Health β Itβs Only Natural!
On February 13, 2023, a Fed. Cir. panel of Judges Prost, Chen and Stoll (Prost writing) held, in Appeal no. 2022-1116, that the asserted claims 1-3 of U.S. Patent No. 8,197, 807 are directed to unpatentable subject matter, namely to … Continue reading →
Senate Subcommittee on IP Feels our PAIN
In lengthy hearings conducted by the Senate Subcommittee on Intellectual Property (of the Committee on the Judiciary) on June 4th and 5th (Parts I and II; Part III will be held on June 11th), the Subcommittee, chaired by Senators Tillis … Continue reading →
Bipartisan “Draft Bill” to Amend ss. 100, 101 and 112 Released for Comment
On Wednesday, Senators Tillis and Coons, along with Reps. Collins, Johnson and Stivers released a draft, bipartisan bill to amend ss.100 and 101 to void the “judicial exceptions” to patent eligibility. Section 112(f) was also amended to tighten up the … Continue reading →
Posted in Patent Eligible Subject Matter
|
Tagged Bergy II, Chakrabarty, Section 101, Section 101 Reform, Section 112(f), Senator Coons, Senator Tillis
|
Leave a comment
Ex parte Ren-Hie Xu β Are Cultured Mammalian Cells Natural Products?
The Examiner in Appeal no. 2017-003416 (Mar. 1, 2019) had rejected this claim as directed to a natural product: β18. An in vitro culture comprising a substantially pure, replenishable population of synchronous primate trophoblast cells, wherein the synchronous primate trophoblast … Continue reading →
Posted in Patent Eligible Subject Matter
|
Tagged blastocyst, Chakrabarty, patentability, Roslin Institute, trophoblast, USPTO
|
1 Comment